{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Pro-Dex, Inc.
Pro-Dex, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Pro-Dex, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, showcasing a P/E ratio of 16 and a price-to-book value of 3.97. The company exhibits strong profitability with a ROCE of 26.48% and ROE of 25.14%, distinguishing itself from riskier peers in the industry.
Is Pro-Dex, Inc. overvalued or undervalued?
As of October 17, 2025, Pro-Dex, Inc. is considered very attractive in valuation due to its strong metrics, including a P/E ratio of 16 and a PEG ratio of 0.18, despite a year-to-date stock decline of -43.91%, suggesting it may be undervalued compared to peers like Prenetics Global Ltd. and Wrap Technologies, Inc.
Pro-Dex, Inc. Hits 52-Week Low at $24.04 Amid Declining Performance
Pro-Dex, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting recent struggles despite a strong one-year performance. The company, with a market cap of USD 116 million, faces challenges in maintaining growth and lacks a dividend yield, raising sustainability concerns.
Pro-Dex, Inc. Hits 52-Week Low at $24.22 Amid Market Challenges
Pro-Dex, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, contrasting with its previous high. Despite this, the company has outperformed the S&P 500 over the past year and maintains a solid return on equity and low debt-to-equity ratio, though it lacks a dividend yield.
Is Pro-Dex, Inc. technically bullish or bearish?
As of September 5, 2025, Pro-Dex, Inc. has shifted to a mildly bearish trend due to a bearish MACD and moving averages, despite a bullish weekly RSI, with significant underperformance compared to the S&P 500.
Is Pro-Dex, Inc. overvalued or undervalued?
As of June 30, 2025, Pro-Dex, Inc. is considered very attractive due to its undervaluation, evidenced by a favorable P/E ratio of 16, a PEG ratio of 0.18, and an EV to EBITDA ratio of 11.51, despite a year-to-date return of -25.65%, while it has outperformed the S&P 500 with a one-year return of 36.31%.
Is Pro-Dex, Inc. technically bullish or bearish?
As of May 2, 2025, Pro-Dex, Inc. shows a mildly bullish trend driven by daily moving averages, despite mixed signals from weekly and monthly indicators suggesting caution.
Is Pro-Dex, Inc. overvalued or undervalued?
As of May 1, 2025, Pro-Dex, Inc. is considered very attractive due to its strong financial metrics, including a P/E ratio of 16 and a PEG ratio of 0.18, significantly outperforming peers and the S&P 500 with a 122.57% return over the past year.
Who are in the management team of Pro-Dex, Inc.?
As of March 2022, the management team of Pro-Dex, Inc. includes Mr. Nicholas Swenson (Independent Chairman), Mr. Richard Van Kirk (President and CEO), Ms. Katrina Philp, and independent directors Mr. Raymond Cabillot, Mr. William Farrell, and Mr. David Hovda.
What does Pro-Dex, Inc. do?
Pro-Dex, Inc. designs and manufactures surgical and dental instruments and motion control products, classified as a micro-cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $17 million and a net profit of $3 million, with a market cap of $139.02 million.
How big is Pro-Dex, Inc.?
As of Jun 18, Pro-Dex, Inc. has a market capitalization of 139.02 million and reported net sales of 64.12 million with a net profit of 9.37 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
